SkinBioTherapeutics plc (LON:SBTX – Get Free Report)’s stock price rose 6.2% on Friday . The company traded as high as GBX 9 and last traded at GBX 6.90. Approximately 2,144,433 shares were traded during mid-day trading, a decline of 50% from the average daily volume of 4,275,483 shares. The stock had previously closed at GBX 6.50.
SkinBioTherapeutics Stock Up 6.2%
The stock’s 50-day moving average price is GBX 9.60 and its two-hundred day moving average price is GBX 12.55. The stock has a market capitalization of £17.88 million, a PE ratio of -22.26 and a beta of 0.47. The company has a debt-to-equity ratio of 11.77, a quick ratio of 10.01 and a current ratio of 6.14.
SkinBioTherapeutics (LON:SBTX – Get Free Report) last released its earnings results on Monday, June 8th. The company reported GBX (0.31) earnings per share for the quarter. The business had revenue of GBX 217 million during the quarter. SkinBioTherapeutics had a negative return on equity of 5.25% and a negative net margin of 8.73%.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
Featured Articles
- Five stocks we like better than SkinBioTherapeutics
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
- ERock IPO: A $1.3B Power Play Solution
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
